172 related articles for article (PubMed ID: 36685546)
41. Surface molecules involved in the activation and regulation of T or natural killer lymphocytes in humans.
Moretta A; Ciccone E; Pantaleo G; Tambussi G; Bottino C; Melioli G; Mingari MC; Moretta L
Immunol Rev; 1989 Oct; 111():145-75. PubMed ID: 2697680
[TBL] [Abstract][Full Text] [Related]
42. In vitro expansion of CD3/TCR- human thymocyte populations that selectively lack CD3 delta gene expression: a phenotypic and functional analysis.
Poggi A; Biassoni R; Pella N; Paolieri F; Bellomo R; Bertolini A; Moretta L; Mingari MC
J Exp Med; 1990 Nov; 172(5):1409-18. PubMed ID: 2146363
[TBL] [Abstract][Full Text] [Related]
43. Cytotoxic T lymphocyte triggering via CD16 is regulated by CD3 and CD8 antigens. Studies with T cell receptor (TCR)-alpha beta+/CD3+16+ and TCR-gamma delta+/CD3+16+ granular lymphocytes.
Oshimi K; Oshimi Y; Yamada O; Wada M; Hara T; Mizoguchi H
J Immunol; 1990 May; 144(9):3312-7. PubMed ID: 2139452
[TBL] [Abstract][Full Text] [Related]
44. Role of CD3 gamma in T cell receptor assembly.
Dietrich J; Neisig A; Hou X; Wegener AM; Gajhede M; Geisler C
J Cell Biol; 1996 Feb; 132(3):299-310. PubMed ID: 8636209
[TBL] [Abstract][Full Text] [Related]
45. Major histocompatibility complex class I molecules modulate activation threshold and early signaling of T cell antigen receptor-gamma/delta stimulated by nonpeptidic ligands.
Carena I; Shamshiev A; Donda A; Colonna M; Libero GD
J Exp Med; 1997 Nov; 186(10):1769-74. PubMed ID: 9362537
[TBL] [Abstract][Full Text] [Related]
46. Targeting the TNF/IAP pathway synergizes with anti-CD3 immunotherapy in T-cell acute lymphoblastic leukemia.
Ávila Ávila A; Nuantang K; Oliveira ML; Druillennec S; Zaniboni B; Lengliné E; Asnafi V; Ghysdael J; Tran Quang C
Blood; 2024 May; 143(21):2166-2177. PubMed ID: 38437728
[TBL] [Abstract][Full Text] [Related]
47. A functional gammadeltaTCR/CD3 complex distinct from gammadeltaT cells is expressed by human eosinophils.
Legrand F; Driss V; Woerly G; Loiseau S; Hermann E; Fournié JJ; Héliot L; Mattot V; Soncin F; Gougeon ML; Dombrowicz D; Capron M
PLoS One; 2009 Jun; 4(6):e5926. PubMed ID: 19536290
[TBL] [Abstract][Full Text] [Related]
48. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
49. Differential pathways for calcium influx activated by concanavalin A and CD3 stimulation in Jurkat T cells.
Pang B; Shin DH; Park KS; Huh YJ; Woo J; Zhang YH; Kang TM; Lee KY; Kim SJ
Pflugers Arch; 2012 Feb; 463(2):309-18. PubMed ID: 22020731
[TBL] [Abstract][Full Text] [Related]
50. Associations between subunit ectodomains promote T cell antigen receptor assembly and protect against degradation in the ER.
Wileman T; Kane LP; Young J; Carson GR; Terhorst C
J Cell Biol; 1993 Jul; 122(1):67-78. PubMed ID: 8314847
[TBL] [Abstract][Full Text] [Related]
51. Partial inefficiency of T cell receptors gamma/delta composed of a heavy (55-kD) gamma chain to mediate cell activation upon binding to specific monoclonal antibodies.
Mingari MC; Tambussi G; Bottino C; Varese P; Moretta A
Ric Clin Lab; 1989; 19(1):39-44. PubMed ID: 2527403
[TBL] [Abstract][Full Text] [Related]
52. Introduction of T cell receptor (TCR)-alpha cDNA has differential effects on TCR-gamma delta/CD3 expression by PEER and Lyon-1 cells.
De Waal Malefyt R; Alarcon B; Yssel H; Sancho J; Miyajima A; Terhorst CP; Spits H; De Vries JE
J Immunol; 1989 May; 142(10):3634-42. PubMed ID: 2523930
[TBL] [Abstract][Full Text] [Related]
53. Double-negative (CD4- CD8-) T cells from adult T-cell leukemia patients also have poor expression of the T-cell receptor alpha beta/CD3 complex.
Suzushima H; Asou N; Nishimura S; Nishikawa K; Wang JX; Okubo T; Naito M; Hattori T; Takatsuki K
Blood; 1993 Feb; 81(4):1032-9. PubMed ID: 8381310
[TBL] [Abstract][Full Text] [Related]
54. CD5 acts as a tyrosine kinase substrate within a receptor complex comprising T-cell receptor zeta chain/CD3 and protein-tyrosine kinases p56lck and p59fyn.
Burgess KE; Yamamoto M; Prasad KV; Rudd CE
Proc Natl Acad Sci U S A; 1992 Oct; 89(19):9311-5. PubMed ID: 1384049
[TBL] [Abstract][Full Text] [Related]
55. Bispecific T-cell engagers for cancer immunotherapy.
Huehls AM; Coupet TA; Sentman CL
Immunol Cell Biol; 2015 Mar; 93(3):290-6. PubMed ID: 25367186
[TBL] [Abstract][Full Text] [Related]
56. Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells.
Bortoletto N; Scotet E; Myamoto Y; D'Oro U; Lanzavecchia A
Eur J Immunol; 2002 Nov; 32(11):3102-7. PubMed ID: 12385030
[TBL] [Abstract][Full Text] [Related]
57. Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules.
Weijtens ME; Willemsen RA; van Krimpen BA; Bolhuis RL
Int J Cancer; 1998 Jul; 77(2):181-7. PubMed ID: 9650549
[TBL] [Abstract][Full Text] [Related]
58. Ligand-induced interactions between butyrophilin 2A1 and 3A1 internal domains in the HMBPP receptor complex.
Hsiao CC; Nguyen K; Jin Y; Vinogradova O; Wiemer AJ
Cell Chem Biol; 2022 Jun; 29(6):985-995.e5. PubMed ID: 35081362
[TBL] [Abstract][Full Text] [Related]
59. The eIg technology to generate Ig-like bispecific antibodies.
Kühl L; Aschmoneit N; Kontermann RE; Seifert O
MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
[TBL] [Abstract][Full Text] [Related]
60. Lineage determination of CD7+ CD5- CD2- and CD7+ CD5+ CD2- lymphoblasts: studies on phenotype, genotype, and gene expression of myeloperoxidase, CD3 epsilon, and CD3 delta.
Yoneda N; Tatsumi E; Teshigawara K; Nagata S; Nagano T; Kishimoto Y; Kimura T; Yasunaga K; Yamaguchi N
Am J Hematol; 1994 Apr; 45(4):310-20. PubMed ID: 7513945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
